Ready to start planning your care? Call us at 800-525-2225 to make an appointment.

Antitumor Assessment

Share

Overview

Elisa de Stanchina

Director

The Antitumor Assessment Core Facility was established in 2003 to provide highly qualified services to foster cancer research and to support early discovery of effective antitumor agents and regimens of therapies at Memorial Sloan Kettering Cancer Center. In particular, the facility provides resources, professional and technical expertise, and advisory services related to the evaluation of agents with potential therapeutic activity. The facility works closely with investigators to establish in vivo mouse models; design and execute pharmacokinetic, toxicity, and in vivo efficacy studies; and determine the best formulation, administration route, and treatment schedule for each new compound, either alone or in combination with other agents.

VIDEO | 04:00

Learn more about the resources and state-of-the-art technology that are available within MSK’s core facilities.

Featured News

Memorial Sloan Kettering Cancer Center Tops Prestigious List of Highly Cited Researchers 2022

Memorial Sloan Kettering Cancer Center Tops Prestigious List of Highly Cited Researchers 2022

Tuesday, November 15, 2022

Memorial Sloan Kettering Cancer Center (MSK) is proud to announce that it is ranked among the top 15 organizations with the greatest number of highly cited scientific researchers worldwide, according to the annual list of Highly Cited Researchers published by the Institute for Scientific Information at Clarivate.

A Closer Look at Breakthroughs in Medicine for Brain Metastasis

A Closer Look at Breakthroughs in Medicine for Brain Metastasis

MSK medical oncologist Bob Li discusses new opportunities in brain metastasis care thanks to innovative technology and medical breakthroughs.

Bottles filled with liquid

Growing Science: A Decade Devoted to Advancing Cancer Research at the Sloan Kettering Institute

Saturday, January 1, 2011

A decade ago, the Sloan Kettering Institute embarked on an effort to broaden and streamline its research activities.

Publications

Chan JM, Quintanal-Villalonga Á, Gao VR, Xie Y, Allaj V, Chaudhary O,
Masilionis I, Egger J, Chow A, Walle T, Mattar M, Yarlagadda DVK, Wang JL, Uddin
F, Offin M, Ciampricotti M, Qeriqi B, Bahr A, de Stanchina E, Bhanot UK, Lai WV,
Bott MJ, Jones DR, Ruiz A, Baine MK, Li Y, Rekhtman N, Poirier JT, Nawy T, Sen
T, Mazutis L, Hollmann TJ, Pe’er D, Rudin CM. Signatures of plasticity,
metastasis, and immunosuppression in an atlas of human small cell lung cancer.
Cancer Cell. 2021 Nov 8;39(11)

Chow A, Schad S, Green MD, Hellmann MD, Allaj V, Ceglia N, Zago G, Shah NS,
Sharma SK, Mattar M, Chan J, Rizvi H, Zhong H, Liu C, Bykov Y, Zamarin D, Shi H,
Budhu S, Wohlhieter C, Uddin F, Gupta A, Khodos I, Waninger JJ, Qin A, Markowitz
GJ, Mittal V, Balachandran V, Durham JN, Le DT, Zou W, Shah SP, McPherson A,
Panageas K, Lewis JS, Perry JSA, de Stanchina E, Sen T, Poirier JT, Wolchok JD,
Rudin CM, Merghoub T. Tim-4+ cavity-resident macrophages impair anti-
tumor CD8+ T cell immunity. Cancer Cell. 2021 Jul
12;39(7)

Ruscetti M, Morris JP 4th, Mezzadra R, Russell J, Leibold J, Romesser PB,
Simon J, Kulick A, Ho YJ, Fennell M, Li J, Norgard RJ, Wilkinson JE, Alonso-
Curbelo D, Sridharan R, Heller DA, de Stanchina E, Stanger BZ, Sherr CJ, Lowe
SW. Senescence-Induced Vascular Remodeling Creates Therapeutic Vulnerabilities
in Pancreas Cancer. Cell. 2020 Apr 16;181(2):424-441.e21. Epub 2020 Mar 31. Erratum in: Cell. 2021 Sep
2;184(18)

Zhao Y, Murciano-Goroff YR, Xue JY, Ang A, Lucas J, Mai TT, Da Cruz Paula AF,
Saiki AY, Mohn D, Achanta P, Sisk AE, Arora KS, Roy RS, Kim D, Li C, Lim LP, Li
M, Bahr A, Loomis BR, de Stanchina E, Reis-Filho JS, Weigelt B, Berger M, Riely
G, Arbour KC, Lipford JR, Li BT, Lito P. Diverse alterations associated with
resistance to KRAS(G12C) inhibition. Nature. 2021 Nov;599(7886)

Zhang Z, Karthaus WR, Lee YS, Gao VR, Wu C, Russo JW, Liu M, Mota JM, Abida
W, Linton E, Lee E, Barnes SD, Chen HA, Mao N, Wongvipat J, Choi D, Chen X, Zhao
H, Manova-Todorova K, de Stanchina E, Taplin ME, Balk SP, Rathkopf DE, Gopalan
A, Carver BS, Mu P, Jiang X, Watson PA, Sawyers CL. Tumor Microenvironment-
Derived NRG1 Promotes Antiandrogen Resistance in Prostate Cancer. Cancer Cell.
2020 Aug 10;38(2)

View All Publications

People

Elisa de Stanchina
Director

Members

Juan (Jane) Qiu, BS — Juan (Jane) Qiu
Senior Research Assistant

Huiyong Zhao, MD — Huiyong Zhao
Senior Research Assistant

Michael Kaufmann
Clinical Research Coordinator

Julia Zaccaria
Research Technician

Santosh Adiraju

QA/GLP Manager

Phoebe Bacchus — Phoebe Bacchus
Research Technician

Sydney Bowker — Sydney Bowker
Research Technician

Qing Chang, PhD — Qing Chang
Scientific Research Lead

Kevin Chen — Kevin Chen
Research Technician

Xiaoping Chen — Xiaoping Chen
Senior Research Assistant

Ana Crawford — Ana Crawford
Lead Research Admin Assistant

Olimpia Gavaudan
Research Technician

Idollia Gunpot
Research Technician

Sabrina Jezerca
Clinical Research Coordinator

Inna Khodos — Inna Khodos
Senior Research Assistant

Amanda Kulick
Senior Research Assistant

Charlene Kwong — Charlene Kwong
Research Project Associate

Jake Lee
Clinical Research Coordinator

Jeanine Lisanti
Clinical Research Coordinator

Laura Liu
QA/GLP Manager

Besnik Qeriqi
Senior Research Assistant

Morgan Temple

Senior Research Technician

Michael Tribuzio
Research Technician

Michael Trombetta
Research Technician

Akiba Waterman
Research Technician

Riley Williams
Senior Research Technician

Open Positions

To learn more about available postdoctoral opportunities, please visit our Career Center

Get in Touch

[email protected]

Director Email
646-888-2142/2160 (Pager: #5735)

Office Phone